Literature DB >> 6307435

A comparison of methods for the production of monodispersed cell suspensions from human primary breast carcinomas.

G J Besch, W H Wolberg, K W Gilchrist, J G Voelkel, M N Gould.   

Abstract

Production of monodispersed cell suspensions from primary human breast tumors is difficult due to the predominant stromal composition of most breast tumors. Our studies were designed to optimize dispersion of breast tumors of known stromal content and histopathology. In a first series of experiments three enzymatic protocols were compared to disperse minced tissue: (A) treatment with collagenase (2 mg/ml) in the presence of 5% serum for 24 hours; (B) treatment with collagenase (6 mg/ml) and DNase (0.002%) in 10% serum for 3 hours; (C) treatment with collagenase (2 mg/ml) for 3 hours followed by pronase (0.075%) for 1 hour. Protocol A produced better cell yields than B or C for all tumors tested. The monodispersed cells were suspended in a 0.3% semi-solid agar with alpha modified Eagles medium (alpha MEM), 10% serum, and selected hormones, then layered over similarly enriched 0.5% semi-solid agar. The cells prepared by protocol A had a higher plating efficiency and larger average colony size than B or C. In a second series of experiments, protocol A was repeated and compared to two additional procedures: (D) treatment with collagenase (2 mg/ml) and hyaluronidase (1 mg/ml) in the presence of 5% serum for 24 hours; and (E) mechanical disaggregation. Protocol D exhibited a small but significant negative difference from A, while E was the least efficient in producing viable monodispersed cells from the tumors. All enzymatically monodispersed cells produced clonal growth in our agar system. However, mechanically dispersed cells gave growth in only 4 of 7 tumors. Protocol A, in addition to yielding the highest number of viable cells per gram of tissue, gave the highest plating efficiency of all protocols tested.

Entities:  

Mesh:

Year:  1983        PMID: 6307435     DOI: 10.1007/bf01806230

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  9 in total

1.  Direct cloning of human ovarian carcinoma cells in agar.

Authors:  A W Hamburger; S E Salmon; M B Kim; J M Trent; B J Soehnlen; D S Alberts; H J Schmidt
Journal:  Cancer Res       Date:  1978-10       Impact factor: 12.701

2.  Growth of cell colonies in soft agar from biopsies of different human solid tumors.

Authors:  Z P Pavelic; H K Slocum; Y M Rustum; P J Creaven; N J Nowak; C Karakousis; H Takita; A Mittelman
Journal:  Cancer Res       Date:  1980-11       Impact factor: 12.701

3.  Normal mammary cells in long term culture. I. development of hormone-dependent functional monolayer cultures and assay of alpha-lactalbumin production.

Authors:  D B Ray; I A Horst; R W Jansen; J Kowal
Journal:  Endocrinology       Date:  1981-02       Impact factor: 4.736

4.  Human breast cell-mediated mutagenesis of mammalian cells by polycyclic aromatic hydrocarbons.

Authors:  M N Gould; L E Cathers; C J Moore
Journal:  Cancer Res       Date:  1982-11       Impact factor: 12.701

5.  Mammary gland cell-mediated mutagenesis of mammalian cells by organ-specific carcinogens.

Authors:  M N Gould
Journal:  Cancer Res       Date:  1980-06       Impact factor: 12.701

6.  Direct cloning of human neuroblastoma cells in soft agar culture.

Authors:  D D Von Hoff; J Casper; E Bradley; J M Trent; A Hodach; C Reichert; R Makuch; A Altman
Journal:  Cancer Res       Date:  1980-10       Impact factor: 12.701

7.  Primary bioassay of human tumor stem cells.

Authors:  A W Hamburger; S E Salmon
Journal:  Science       Date:  1977-07-29       Impact factor: 47.728

8.  Primary culture of human mammary epithelial cells embedded in collagen gels.

Authors:  J Yang; R Guzman; J Richards; V Jentoft; M R DeVault; S R Wellings; S Nandi
Journal:  J Natl Cancer Inst       Date:  1980-08       Impact factor: 13.506

9.  Characterization of cells obtained by mechanical and enzymatic means from human melanoma, sarcoma, and lung tumors.

Authors:  H K Slocum; Z P Pavelic; Y M Rustum; P J Creaven; C Karakousis; H Takita; W R Greco
Journal:  Cancer Res       Date:  1981-04       Impact factor: 12.701

  9 in total
  6 in total

1.  New piperidine derivative DTPEP acts as dual-acting anti-breast cancer agent by targeting ERα and downregulating PI3K/Akt-PKCα leading to caspase-dependent apoptosis.

Authors:  A Arun; M I Ansari; P Popli; S Jaiswal; A K Mishra; A Dwivedi; K Hajela; R Konwar
Journal:  Cell Prolif       Date:  2018-08-09       Impact factor: 6.831

2.  Effect of cell isolation methods and drug concentration on the use of the Differential Staining Cytotoxicity (DiSC) assay with solid tumours.

Authors:  A G Bosanquet; S Forskitt
Journal:  Cytotechnology       Date:  1989-08       Impact factor: 2.058

3.  Relationship between histopathology and in vitro clonogenicity in breast cancer.

Authors:  J Moezzi; F Ali-Osman; G L Nicholson; J S Ungerleider; M J Murphy
Journal:  Breast Cancer Res Treat       Date:  1986       Impact factor: 4.872

4.  An optimized disaggregation method for human lung tumors that preserves the phenotype and function of the immune cells.

Authors:  Jon G Quatromoni; Sunil Singhal; Pratik Bhojnagarwala; Wayne W Hancock; Steven M Albelda; Evgeniy Eruslanov
Journal:  J Leukoc Biol       Date:  2014-10-30       Impact factor: 4.962

5.  Cultivation of human breast carcinoma in soft agar. Experience with 237 fresh tumour specimens.

Authors:  L Ottestad; K M Tveit; H K Høifødt; J M Nesland; S Vaage; J Høie; E Lund; A Pihl
Journal:  Br J Cancer       Date:  1988-07       Impact factor: 7.640

6.  Chemotherapeutic Potential of 2-[Piperidinoethoxyphenyl]-3-Phenyl-2H-Benzo(b)pyran in Estrogen Receptor- Negative Breast Cancer Cells: Action via Prevention of EGFR Activation and Combined Inhibition of PI-3-K/Akt/FOXO and MEK/Erk/AP-1 Pathways.

Authors:  Ruchi Saxena; Vishal Chandra; Murli Manohar; Kanchan Hajela; Utsab Debnath; Yenamandra S Prabhakar; Karan Singh Saini; Rituraj Konwar; Sandeep Kumar; Kaling Megu; Bal Gangadhar Roy; Anila Dwivedi
Journal:  PLoS One       Date:  2013-06-19       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.